Carbapenem-resistant Enterobacteriaceae are amongst the most feared pathogens due to
severely limited treatment options. In response to this threat, three novel β-lactamase …

Resistance to β-lactam antibiotics in Gram-negative bacteria is commonly associated with
production of β-lactamases, including extended-spectrum β-lactamases (ESBLs) and …

As the incidence of Gram-negative bacterial infections for which few effective treatments
remain increases, so does the contribution of drug-hydrolyzing β-lactamase enzymes to this …

Abstract β-Lactamase inhibitors (BLIs) have played an important role in combatting β-lactam
resistance in Gram-negative bacteria, but their effectiveness has diminished with the …

The limited armamentarium against drug-resistant Gram-negative bacilli has led to the
development of several novel β-lactam–β-lactamase inhibitor combinations (BLBLIs). In this …

Relebactam (formerly known as MK-7655) is a non-β-lactam, bicyclic diazabicyclooctane, β-
lactamase inhibitor that is structurally related to avibactam, differing by the addition of a …

Avibactam, which is the first non-β-lactam β-lactamase inhibitor to be introduced for clinical
use, is a broad-spectrum serine β-lactamase inhibitor with activity against class A, class C …

Avibactam is a novel non-β-lactam β-lactamase inhibitor that inhibits a wide range of β-
lactamases. These include class A, class C, and some class D enzymes, which erode the …

Vaborbactam (formerly RPX7009) is a new beta-lactamase inhibitor based on a cyclic
boronic acid pharmacophore. The spectrum of beta-lactamase inhibition by vaborbactam …

Vaborbactam (formerly RPX7009) is a member of a new class of β-lactamase inhibitor with
pharmacokinetic properties similar to those of many β-lactams, including carbapenems. The …